Breast cancer

Жукова, Л. Г.; Andreeva, Iuliia I.; Завалишина, Л Э; Zakiriakhodzhaev, Aziz D.; Koroleva, Irina; Nazarenko, Aleksei V.; Палтуев, Р. М.; Parokonnaya, A. A.; Петровский, А. В.; Portnoi, Sergei M.; Семиглазов, Владимир; Semiglazova, T. Yu.; Стенина, М. Б.; Stepanova, Aleksandra M.; Trofimova, O. P.; Tyulyandin, Sergey A.; Франк, Г. А.; Фролова, М. А.; Shatova, Iuliana S.; Nevolskikh, A. A.; Иванов, С. А.; Khailova, Zhanna V.; Gevorkian, Tigran G.

doi:10.26442/18151434.2021.1.200823

Cited by 6 publications

(3 citation statements)

References 198 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Оценка краев резекции является обязательным этапом органосохраняющего лечения при DCIS; в отличие от инвазивного рака, при котором «чистым» краем является отсутствие опухолевых клеток по краю резекции, онкологические сообщества рекомендуют считать негативными краями при карциноме in situ отступ в >2 мм от края опухоли [22,23]. Такое мнение отражает результаты метаанализа 20 исследований по DCIS с включением 7883 больных, в котором показано, что частота локальных рецидивов после органосохраняющего лечения составляет 11% и напрямую зависит от расстояния от края резекции от опухоли.…”

Section: локальное лечение Dcis: настоящее и будущие перспективыunclassified

“…Однако единственным фактором для выбора адъювантной системной терапии в настоящий момент при DCIS является наличие гормоноположительного статуса опухоли. Адъювантная системная терапия при DCIS направлена на снижение риска развития инвазивного рака ипсилатеральной и контрлатеральной молочной железы и включает эндокринотерапию тамоксифеном или ингибиторами ароматазы при подтвержденном ER+ статусе [23,29]. Основой для выработки рекомендаций по эндокринотерапии DCIS стало исследование NSABP B-24, в котором изучена роль эндокринотерапии тамоксифеном у больных с DCIS.…”

Section: рецепторный статус Dcis: предикторная и прогностическая рольunclassified

See 1 more Smart Citation

Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization

et al. 2021

View full text Add to dashboard Cite

Ductal carcinoma in situ (DCIS) is an extremely heterogeneous disease in terms of clinical manifestations, morphological changes, and expression of biomarkers, which determine the risk of subsequent development of an invasive breast cancer (BC). Diagnosis and treatment of DCIS prevents the development of invasive tumors (which reduces the potential risk of death from BC); however, the prognostic value of local treatment depends on the biological characteristics of its. The tumor grade, presence of comedonecrosis and expression of estrogen receptors are the key prognostic factors in DCIS for the treatment tactics and prognosis. The clinical symptoms of DCIS are very scarce, the most of tumors is diagnosed by screening mammography; the typical sign of DCIS is malignant microcalcifications or changes of breast architectonic. The sensitivity of mammography, ultrasound and MRI directly depend on the biological characteristics of DCIS. Surgical treatment (breast-conserving surgery or mastectomy) significantly reduces the risk of BC death in women with DCIS G2/G3, and radiotherapy after breast-conserving surgery reduce the risk of local recurrence of non-invasive and invasive BC. The choice of the local treatment (breast-conserving surgery radiation therapy vs mastectomy) depend on such factors as: tumor size, localization, clear margins, and biological characteristics of DCIS. In contrast to invasive cancers, the negative margin in DCIS is more than 2 mm from the tumor. Regional lymph node involvement in DCIS occurs in less than 1% of cases; however, microinvasion is found in analyze the surgical specimen in 15% of patients, which raises the question about regional staging. Risk factors for microinvasion in DCIS are age less than 55 years, tumor lesion size more than 4.0 cm, DCIS grade G3, and tumor palpability. Adjuvant endocrine therapy with tamoxifen significantly reduces the 10-year risk of invasive recurrence by 51%, the risk of contralateral BC by 50% and the risk of death by 40%, but only for hormone-positive DCIS. HER2 overexpression is found in DCIS significantly often (up to 40% of cases) than in invasive BC, HER2+ status correlates with DCIS high grade G3, the presence of comedonecrosis and with increased risk of relapse (both non-invasive and invasive) but is not a reason for anti-HER2 therapy. DCIS low risk and DCIS high risk have not only different morphological characteristics, but also different models of biological behavior, which must be considered in the different choice of treatment tactics.

show abstract

Section: локальное лечение Dcis: настоящее и будущие перспективыunclassified

Section: рецепторный статус Dcis: предикторная и прогностическая рольunclassified

Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Все перечисленные моменты определяют настоятельную необходимость и делают чрезвычайно актуальными исследования в области разработки новых химиотерапевтических средств, которые справлялись бы с РМЖ [10,11].…”

Section: Introductionunclassified

Antitumor activity of three new azoloazine derivatives in orthotopic transplantation model of human breast cancer cells into mice

Al-Humairi,

Speransky,

Novochadov

et al. 2024

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common types of malignant tumors, which makes scientific research in this area extremely relevant. The difficulties of breast cancer chemotherapy stimulate the search for new drugs to treat this nosology. Derivatives of imidazotriazine and imidazotetrazine, which are analogues of the antitumor drug temozolamide, can be ones of the promising drugs in this regard.The aim of the work was to evaluate the antitumor activity of three new azoloazine derivatives in a xenogeneic breast cancer model in mice in vivo.Materials and methods. A study was conducted on a xenogeneic model of BC. After the immunosuppression with azathioprine, 48 white BALB/c mice were injected with MCF-7 cells, test derivatives, and the reference drug epirubicin at doses of 1/2 IC50 and 1/10 IC50, into the base of the mammary gland once. The body weight of the mice was monitored; on the 15th day, at the end of the experiment, the relative volume was assessed.Results and discussion. Among the three compounds studied, imidazotetrazine 1 showed the most encouraging results: stopping the loss of body weight in the mice caused by the administration of tumor cells, and reducing the tumor volume on the 15th day of the experiment to 50.6% of that in the control when using a dose of 1/10 IC50, up to 39.2% – when using a dose of 1/2 IC50, which significantly exceeded the values of the reference drug epirubicin and the values in the control group. In the histological examination, the signs of spread and preservation of tumor cells viability of the MCF-7 line after its administration were minimal, the value of the histological malignancy index decreased by 9.3% of the control value.Conclusion. Among the tested azoloazine derivatives, 3-cyclohexyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-N-piperidinylcarboxamide is the undisputed leader, causing inhibition of the tumor growth in a xenogeneic model in vivo.

show abstract

Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice

Kolyadina

2021

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life expectancy of patients. This review presents the features of the mechanism of action of CDK4/6 inhibitors, the most significant and updated results of large, randomized trials with ribociclib (MONALEESA-2, MONALEESA-3, and MONALEESA-7) assessing the efficacy and safety of combined endocrine therapy with various endocrine partners in a population of premenopausal women and menopausal patients. The prospects for the use of CDK4/6 inhibitors for therapy patients with visceral crisis are shown.

show abstract

Breast cancer

Cited by 6 publications

References 198 publications

Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization

Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization

Antitumor activity of three new azoloazine derivatives in orthotopic transplantation model of human breast cancer cells into mice

Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice

Contact Info

Product

Resources

About